Vontobel Holding Ltd. Reduces Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Vontobel Holding Ltd. reduced its holdings in Edwards Lifesciences Corporation by 1.4% in the second quarter, owning approximately 0.06% of the company after selling 5,316 shares.
• Analysts are optimistic about Edwards Lifesciences, with several like Barclays and Deutsche Bank raising their price objectives, indicating a consensus target price of $87.06 and a "Moderate Buy" rating.
• Insider activity includes Larry L. Wood selling 8,950 shares, representing a 4.15% decrease in his position, highlighting ongoing shifts in stock ownership among executives.

Vontobel Holding Ltd. decreased its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 1.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 379,656 shares of the medical research company's stock after selling 5,316 shares during the quarter. Vontobel Holding Ltd. owned about 0.06% of Edwards Lifesciences worth $29,693,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Maryland State Retirement & Pension System lifted its position in Edwards Lifesciences by 2.1% during the second quarter. Maryland State Retirement & Pension System now owns 27,974 shares of the medical research company's stock valued at $2,188,000 after buying an additional 579 shares during the period. Aurora Investment Managers LLC. purchased a new position in Edwards Lifesciences during the second quarter valued at $212,000. Spectrum Asset Management Inc. NB CA lifted its position in Edwards Lifesciences by 1.4% during the second quarter. Spectrum Asset Management Inc. NB CA now owns 39,083 shares of the medical research company's stock valued at $3,057,000 after buying an additional 540 shares during the period. Mirova US LLC lifted its position in Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company's stock valued at $229,257,000 after buying an additional 1,054,301 shares during the period. Finally, BankPlus Trust Department lifted its position in Edwards Lifesciences by 3.4% during the second quarter. BankPlus Trust Department now owns 11,907 shares of the medical research company's stock valued at $931,000 after buying an additional 391 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on EW shares. Barclays raised their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research report on Friday, July 25th. Morgan Stanley raised their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Deutsche Bank Aktiengesellschaft raised their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. Finally, Wall Street Zen downgraded Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a report on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $87.06.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

NYSE EW opened at $75.17 on Friday. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00. The stock has a 50-day moving average of $78.20 and a 200 day moving average of $76.08. The company has a market capitalization of $44.13 billion, a price-to-earnings ratio of 10.82, a PEG ratio of 3.64 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the company earned $0.70 EPS. Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.